Literature DB >> 7742541

Functional expression of adhesion receptors and costimulatory molecules by fresh and immortalized B-cell non-Hodgkin's lymphoma cells.

F A Vyth-Dreese1, T A Dellemijn, J W van Oostveen, C A Feltkamp, A Hekman.   

Abstract

Peripheral blood lymphocytes of a patient with follicular B-cell non-Hodgkin's lymphoma (B-NHL) were immortalized in vitro by Epstein-Barr virus (EBV). Eight cell lines were obtained (termed BNS1, BNS2-1 through BNS2-7), which showed a pattern of idiotypic (id) Ig surface expression and Ig JH and kappa gene rearrangement, identical to that of the parent cells (termed NS), confirming their neoplastic origin. Induction of allogeneic T-cell proliferation by NS cells was mediated by HLA-DR, leukocyte function-associated antigen-1 (LFA-1), LFA-3, B7-1/CD80, and CTLA4 and resulted in the upregulation (LFA-3, intercellular adhesion molecule-1 [ICAM-1], CD40) and induction (B7-1/CD80, B7-2/CD86, L16/activated LFA-1) of accessory molecules on NS cells. In turn, responder T lymphocytes were induced to express B7-1/CD80, B7-2/CD86, CD40 ligand (CD40L), ICAM-1, L16/activated LFA-1, and HLA-DR, reflecting bidirectional signaling between T lymphocytes and B-NHL cells. Preactivation of NS cells by EBV transformation or CD40 engagement resulted in enhanced expression of accessory molecules and abolished the requirement for accessory cells during allostimulation. These resting and activated clonal B cells will be useful in further dissecting the requirements for B-NHL costimulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742541

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

Authors:  Pedro Horna; Alex Cuenca; Fengdong Cheng; Jason Brayer; Hong-Wei Wang; Ivan Borrello; Hyam Levitsky; Eduardo M Sotomayor
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

3.  Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.

Authors:  Raphaël F Rousseau; Ettore Biagi; Aurélie Dutour; Eric S Yvon; Michael P Brown; Tiffany Lin; Zhuyong Mei; Bambi Grilley; Edwina Popek; Helen E Heslop; Adrian P Gee; Robert A Krance; Uday Popat; George Carrum; Judith F Margolin; Malcolm K Brenner
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

4.  The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.

Authors:  Ronjon Chakraverty; Megan Sykes
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

5.  Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.

Authors:  Guili Hu; Yang Liu; Hong Li; Dekuang Zhao; Liuqing Yang; Jiangen Shen; Xuejun Hong; Xuetao Cao; Qingqing Wang
Journal:  Cell Mol Immunol       Date:  2010-04-26       Impact factor: 11.530

Review 6.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

7.  Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma.

Authors:  F A Vyth-Dreese; H Boot; T A Dellemijn; D M Majoor; L C Oomen; J D Laman; M Van Meurs; R A De Weger; D De Jong
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.